KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 89 filers reported holding KEROS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,284 | -4.6% | 2,236 | +20.3% | 0.00% | 0.0% |
| Q2 2023 | $74,695 | +24.0% | 1,859 | +31.8% | 0.00% | +50.0% |
| Q1 2023 | $60,250 | -16.8% | 1,411 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $72,455 | +36.7% | 1,411 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $53,000 | +76.7% | 1,411 | +29.2% | 0.00% | +100.0% |
| Q2 2022 | $30,000 | -49.2% | 1,092 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $59,000 | -7.8% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $64,000 | +48.8% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $43,000 | -6.5% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $46,000 | -31.3% | 1,092 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $67,000 | -13.0% | 1,092 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $77,000 | +220.8% | 1,092 | +77.6% | 0.00% | +300.0% |
| Q3 2020 | $24,000 | +4.3% | 615 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $23,000 | – | 615 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |